NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Buy IMNN with Qtrade Free IMNN Stock Alerts $1.32 +0.01 (+0.76%) (As of 12:37 PM ET) Add Compare Share Share Today's Range$1.29▼$1.3250-Day Range$0.57▼$1.9352-Week Range$0.48▼$2.00Volume14,628 shsAverage Volume176,497 shsMarket Capitalization$12.41 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Imunon alerts: Email Address Imunon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside898.2% Upside$13.00 Price TargetShort InterestHealthy4.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.27) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.45 out of 5 starsMedical Sector708th out of 924 stocksPharmaceutical Preparations Industry321st out of 426 stocks 3.5 Analyst's Opinion Consensus RatingImunon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImunon has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.96% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently increased by 4.53%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMNN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Imunon this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IMNN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.84% of the stock of Imunon is held by insiders.Percentage Held by InstitutionsOnly 4.47% of the stock of Imunon is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($2.27) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About Imunon Stock (NASDAQ:IMNN)Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Read More IMNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNN Stock News HeadlinesApril 28, 2024 | finance.yahoo.comImunon, Inc. (IMNN)April 25, 2024 | americanbankingnews.comImunon (NASDAQ:IMNN) Trading Down 2.3%May 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 18, 2024 | finance.yahoo.comIMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101April 18, 2024 | globenewswire.comIMUNON's IND Application Cleared to Begin Human Testing of IMNN-101April 11, 2024 | finanznachrichten.deImunon, Inc.: IMUNON Reports Compliance with Nasdaq Listing RequirementsApril 11, 2024 | globenewswire.comIMUNON Reports Compliance with Nasdaq Listing RequirementsMarch 30, 2024 | seekingalpha.comImunon, Inc. (IMNN) Q4 2023 Earnings Call TranscriptMay 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.March 28, 2024 | globenewswire.comIMUNON Reports 2023 Financial Results and Provides Business UpdateMarch 25, 2024 | globenewswire.comIMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating LossesMarch 21, 2024 | globenewswire.comIMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024March 15, 2024 | finanznachrichten.deImunon, Inc.: IMUNON Announces Leadership ChangeMarch 14, 2024 | uk.investing.comIMUNON CEO steps down, Executive Chairman takes helmMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Imunon (IMNN) and CalciMedica (CALC)March 13, 2024 | globenewswire.comIMUNON Files IND Application to Begin Human Testing of IMNN-101March 12, 2024 | globenewswire.comIMUNON Announces Leadership ChangeMarch 2, 2024 | uk.investing.comIMUNON reports promising vaccine study resultsFebruary 29, 2024 | globenewswire.comIndependent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5February 28, 2024 | benzinga.comWhy Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionFebruary 28, 2024 | msn.comIMUNON continues subject enrolment in Phase I/II ovarian cancer trialFebruary 27, 2024 | finance.yahoo.comMemorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerFebruary 27, 2024 | globenewswire.comMemorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerFebruary 22, 2024 | globenewswire.comIMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal VaccineFebruary 16, 2024 | wsj.comBicycle Therapeutics Ltd. ADRDecember 11, 2023 | finance.yahoo.comIMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 20, 2023 | finance.yahoo.comImunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call TranscriptSee More Headlines Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/02/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMNN CUSIPN/A CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees33Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$13.00 Low Stock Price Target$13.00 Potential Upside/Downside+898.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,510,000.00 Net MarginsN/A Pretax Margin-23,541.60% Return on Equity-98.04% Return on Assets-66.49% Debt Debt-to-Equity RatioN/A Current Ratio2.47 Quick Ratio2.47 Sales & Book Value Annual Sales$500,000.00 Price / Sales24.48 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.92Miscellaneous Outstanding Shares9,400,000Free Float9,039,000Market Cap$12.24 million OptionableNot Optionable Beta2.04 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Michael H. Tardugno (Age 73)Executive Chairman Dr. Khursheed Anwer M.B.A. (Age 64)Ph.D., Executive VP & Chief Scientific Officer Comp: $632.26kMr. Timothy J. Tumminello CPA (Age 66)Chief Accounting Officer & Controller Comp: $108.31kDr. Sebastien Hazard M.D. (Age 52)Executive VP & Chief Medical Officer Key CompetitorsAkari TherapeuticsNASDAQ:AKTXElevai LabsNASDAQ:ELABMIRA PharmaceuticalsNASDAQ:MIRAAgeX TherapeuticsNYSE:AGERedHill BiopharmaNASDAQ:RDHLView All Competitors IMNN Stock Analysis - Frequently Asked Questions Should I buy or sell Imunon stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Imunon in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMNN shares. View IMNN analyst ratings or view top-rated stocks. What is Imunon's stock price target for 2024? 1 equities research analysts have issued 12-month target prices for Imunon's shares. Their IMNN share price targets range from $13.00 to $13.00. On average, they anticipate the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 898.2% from the stock's current price. View analysts price targets for IMNN or view top-rated stocks among Wall Street analysts. How have IMNN shares performed in 2024? Imunon's stock was trading at $0.68 at the beginning of 2024. Since then, IMNN stock has increased by 91.5% and is now trading at $1.3023. View the best growth stocks for 2024 here. When is Imunon's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IMNN earnings forecast. How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:IMNN) issued its quarterly earnings data on Thursday, March, 28th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.07. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMNN) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsProtect Your Bank Account Before It’s Too LateWeiss RatingsYour bank is lying to you.MyBankTrackerTruth about Trump you’ve never heardPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
